Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + vinorelbine
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Epirubicin + vinorelbine is a combination chemotherapy regimen used primarily in the treatment of metastatic and advanced breast cancer. Epirubicin is an anthracycline antineoplastic agent that exerts its cytotoxic effects by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to inhibition of nucleic acid and protein synthesis. Vinorelbine is a semi-synthetic vinca alkaloid that disrupts microtubule assembly during mitosis by binding to tubulin, resulting in cell cycle arrest at metaphase. The combination has demonstrated significant activity as first-line therapy for metastatic breast cancer with manageable toxicity profiles[1][2][3][4].
- Other names
- Epirubicin/Vinorelbine combination
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on epirubicin + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + vinorelbine.